Phase IV Study — Post-Marketing Surveillance
Phase IV Post-Marketing Surveillance Study · Also known as: post-marketing surveillance study, post-approval study, Phase 4 study, PMS study
A Phase IV study is a post-marketing surveillance study conducted after a drug, device, or intervention has received regulatory approval. Its primary purpose is to monitor long-term safety, detect rare adverse events, assess effectiveness in routine clinical practice, and explore new indications or populations not adequately represented in earlier trials. Phase IV evidence accumulates continuously throughout a product's commercial life.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
+1 more
When to use it
Use a Phase IV study when a product has received regulatory approval and long-term safety monitoring, rare adverse-event detection, or real-world effectiveness data are required. It is the appropriate design when you need to study populations excluded from pre-approval trials, evaluate comparative effectiveness against standard of care in routine practice, assess adherence and patient-reported outcomes, or fulfil a post-market commitment imposed by a regulatory agency. Do not use a Phase IV study as a substitute for a properly powered Phase III trial when the efficacy question has not yet been answered — regulators do not accept Phase IV evidence for primary efficacy claims. Also avoid applying a Phase IV label to investigator-initiated studies that lack pharmacovigilance infrastructure or a systematic adverse-event reporting plan.
Strengths & limitations
- Detects rare adverse events (incidence below 1 in 1,000) that pre-approval trials lack statistical power to identify.
- Captures effectiveness and safety in the real-world population, including elderly patients, those with comorbidities, and polypharmacy users.
- Can fulfil mandatory regulatory post-marketing commitments and support label updates or new-indication approvals.
- Large sample sizes accumulated over long follow-up periods yield precise incidence estimates for uncommon outcomes.
- Provides comparative effectiveness evidence against active comparators used in routine practice.
- Observational Phase IV designs are vulnerable to confounding by indication, selection bias, and reporting bias that RCTs control by randomization.
- Spontaneous adverse-event reporting systems substantially underestimate true incidence due to voluntary and incomplete reporting.
- Long follow-up and large sample requirements make Phase IV studies expensive and logistically complex.
- Cannot establish primary efficacy for new indications — regulatory bodies require a new Phase III trial for such claims.
Frequently asked
What is the difference between Phase IV and Phase III?
Phase III trials are randomized, placebo- or active-controlled studies conducted before regulatory approval to establish efficacy and safety in a selected study population. Phase IV studies occur after approval, typically in observational or registry designs, in a broader real-world population, focusing on long-term safety, rare events, and effectiveness under routine conditions rather than controlled trial conditions.
Are Phase IV studies always observational?
No. Although most Phase IV studies are observational (cohort, case-control, or registry designs), some are randomized post-approval trials used to compare the approved therapy against an active comparator in a new population, to support a new indication, or to satisfy a regulatory post-marketing commitment. The defining feature is that they occur after regulatory approval, not that they lack randomization.
What is a spontaneous reporting system and how reliable is it?
Spontaneous reporting systems (such as FDA MedWatch or EudraVigilance) collect voluntary adverse-event reports from healthcare providers and patients. They are useful for generating safety signals rapidly but are known to substantially undercount true adverse-event rates — underreporting estimates range from 1% to 10% of actual events. They should be used for signal detection, not for estimating absolute incidence, which requires active surveillance designs.
What is a PSUR?
A Periodic Safety Update Report (PSUR) is a regulatory document submitted by the marketing authorisation holder to regulatory agencies (FDA, EMA, and others) at defined intervals after approval. It summarises all available global safety information — spontaneous reports, clinical trial data, literature — and evaluates whether the benefit-risk balance of the product remains favourable.
Can Phase IV data support approval of a new indication?
Generally no. Observational Phase IV data can generate hypotheses and inform the design of a new trial, but regulatory agencies require randomized controlled trial evidence (typically a new Phase III programme) to approve a new indication. In rare circumstances, strong real-world evidence may supplement or inform a regulatory submission, but it does not replace prospective trial evidence for a primary efficacy claim.
Sources
How to cite this page
ScholarGate. (2026, June 3). Phase IV Post-Marketing Surveillance Study. ScholarGate. https://scholargate.app/en/epidemiology/phase-iv-study
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Case-control studyEpidemiology↔ compare
- Cohort StudyEpidemiology↔ compare
- Cross-sectional epidemiological studyEpidemiology↔ compare
- Phase III clinical trialEpidemiology↔ compare
- Randomized clinical trialEpidemiology↔ compare